详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

RNA sequencing of myeloid sarcoma, shed light on myeloid sarcoma stratification

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, People's Republic of China. [2]Department of Gastrointestinal Surgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, People's Republic of China. [3]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, People's Republic of China. [4]Department of Pathology, West China Hospital of Sichuan University, Chengdu, People's Republic of China. [5]Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, People's Republic of China.

出处：

DOI：

摘要：

Myeloid sarcoma (MS) is a rare, extramedullary tumor consisting of myeloid blasts. Little is known about the genetic background of MS and the prognostic value of genetic abnormalities in MS. In particular, the broad variety of gene fusions that occur in MS is marginally covered by traditional testing methods due to lack of fresh tumor specimens.Here, we analyzed the clinical and genetic features of 61 MS cases. We performed RNA sequencing (RNA-seq) on formalin-fixed paraffin-embedded (FFPE) or fresh samples to analyze fusion genes in 26 cases. In addition, we performed genetic abnormalities-based risk stratification using fusion genes and gene mutations.A total of 305 fusion genes were identified in 22 cases, including the following five recurrent fusion genes: RUNX1-RUNX1T1, CBFβ-MYH11, ETV6-MECOM, FUS-ERG, and PICALM-MLLT10. The prognosis in the adverse-risk group was significantly worse than that in the favorable/intermediate-risk group (median survival: 12 months vs. not reached; p = 0.0004).These results indicated the efficacy of RNA-seq using FFPE-derived RNA as a clinical routine for detecting fusion genes, which can be used as markers for risk stratification in MS.© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

第一作者：

第一作者机构： [1]Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, People's Republic of China. [3]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, People's Republic of China. [5]Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, People's Republic of China. [*1]Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Guoxuexiang 37, Chengdu 610041, P.R. China. [*2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Guoxuexiang 37, Chengdu 610041, P.R. China.

推荐引用方式(GB/T 7714)：

APA：

MLA：